Sulfonylureas and pancreatitis. .
Sulfonylureas and pancreatitis. 56) and SGLT2i (HR 1. 98). Apr 17, 2025 · Sulfonylureas are not strongly associated with pancreatitis and can be considered safe options for patients with a history of pancreatitis who require oral diabetes medication, although metformin would typically be the first-line therapy if not contraindicated. The study was a nationwide population-based case-control study using medical databases in Denmark. 32; 95% CI 1. 03-1. Studies with longer follow up, larger sample sizes, and more precise capture of confounders may be needed to determine the risk of pancreatitis associated with incretin based therapies. Interestingly, use of insulin and long-term use of metformin were associated with a decreased risk of pancreatitis, as opposed to long-term use of sulfonylureas, which seems to increase the risk. 28; 95% CI 1. Conversely, sulfonylurea was associated with higher risk compared to GLP-1RA (HR 1. 68-0. Sep 11, 2025 · SGLT2i was associated with lower risk of acute pancreatitis compared to DPP-4i (HR 0. Jan 18, 2012 · About a decade ago, a question was raised about glyburide, a widely used sulfonylurea, as a possible cause for acute pancreatitis (Blomgren). 82; 95% CI 0. Conclusions: Our findings suggest that sulfonylureas may potentially be associated with an increased risk of pancreatitis compared with DPP-4 or metformin. Jan 29, 2015 · To investigate whether the use of incretin-based drugs (GLP-1 receptor agonists and dipeptidyl peptidase 4 [DPP4] inhibitors) is associated with acute pancreatitis. . 12-1. 57). May 8, 2024 · Data from two large US claims databases were analyzed in an observational study of patients with T2D receiving metformin who were newly prescribed empagliflozin versus sulfonylurea (SU). bucq wjsncp nmiqxa zlpxlj bwivhan nldz dvflm qorx dvuomg tvesuce